Schrodinger

Yahoo Finance • last month

Hasbro And 2 Other Stocks That May Be Priced Below Their Estimated Value

As the U.S. stock market navigates a holiday-shortened week, major indices like the Dow Jones, S&P 500, and Nasdaq have seen slight declines following a previous upward trend. In this fluctuating environment, identifying stocks that may be... Full story

Yahoo Finance • last month

3 Stocks Estimated To Be Priced Below Value In December 2025

As the major stock indexes in the United States continue to log weekly gains, with the S&P 500, Dow Jones Industrial Average, and Nasdaq all showing positive momentum over a holiday-shortened week, investors remain keenly focused on identi... Full story

Yahoo Finance • 2 months ago

BofA Upgrades Schrödinger (SDGR) to Buy After Strategic Pivot to Software

Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc. (NASDAQ:SDGR) from Neutral to Buy, with a $24 price target. BofA stated this move is a result of... Full story

Yahoo Finance • 2 months ago

Cathie Wood tilts toward Robinhood, Bitcoin ETFs, trims Tesla, Iridium

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and sate... Full story

Yahoo Finance • 2 months ago

3 Stocks Estimated To Be Trading Below Intrinsic Value By At Least 41.3%

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, major indices like the S&P 500 and Dow Jones Industrial Average are nearing record highs, reflecting investor optimism. In this bu... Full story

Yahoo Finance • 4 months ago

AI in Biotechnology Market to Reach $11.4 Billion by 2030

BCC Research LLC “BCC Research analyzes how AI-driven discovery tools, predictive analytics, and scalable cloud platforms are transforming biotechnology's future.” Boston, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) is... Full story

Yahoo Finance • 6 months ago

Schrodinger downgraded at Citi after clinical program exit

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Citi downgraded Schrodinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) to Neutral from Buy after the AI-focused biotech announced its decision to discontinue a... Full story

Yahoo Finance • 6 months ago

Schrödinger discontinues leukemia drug after patient deaths

NEW YORK - Schrödinger, Inc. (NASDAQ:SDGR), a $1.46 billion market cap biotech company with a strong balance sheet showing more cash than debt, announced Thursday it has discontinued the clinical development program for SGR-2921, its CDC7... Full story

Yahoo Finance • 6 months ago

Barclays initiates Schrodinger stock with Overweight rating on upcoming catalysts

Investing.com - Barclays initiated coverage on Schrodinger (NASDAQ:SDGR) with an Overweight rating and a $25.00 price target on Thursday. The stock, currently trading at $19.84 with a market capitalization of $1.46 billion, has shown volat... Full story

Yahoo Finance • 6 months ago

Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program

Earnings Call Insights: Schrödinger, Inc. (SDGR) Q2 2025 MANAGEMENT VIEW * CEO Ramy Farid highlighted "very solid progress in the first half of 2025" with total revenue of $54.8 million in the second quarter, a 16% increase year-over-y... Full story

Yahoo Finance • 7 months ago

Schrodinger stock maintains Buy rating at Citi on Ajax collaboration

Investing.com - Citi has reiterated a Buy rating and $39.00 price target on Schrodinger (NASDAQ:SDGR) following the company’s announcement of an expanded research collaboration with Ajax Therapeutics. According to InvestingPro data, this t... Full story

Yahoo Finance • 7 months ago

Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration

NEW YORK/CAMBRIDGE - Ajax Therapeutics, Inc. and Schrödinger, Inc. (NASDAQ:SDGR), a $1.56 billion market cap biotech company with robust revenue growth of 22% over the last twelve months, announced Thursday they are expanding their exclusi... Full story

Yahoo Finance • 7 months ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

NEW YORK & CAMBRIDGE, Mass., July 17, 2025--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. Th... Full story

Yahoo Finance • 7 months ago

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

Investing.com -- Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts in a sector under pre... Full story

Yahoo Finance • 7 months ago

Schrodinger stock rating assumed by Morgan Stanley at Equalweight

Investing.com - Morgan Stanley has assumed coverage on Schrodinger (NASDAQ:SDGR), currently trading at $20.96, with an Equalweight rating and a price target of $28.00, down from the previous $31.00. According to InvestingPro data, the stoc... Full story

Yahoo Finance • 7 months ago

Schrödinger gets Fast Track status for SGR-1505

[Model of DNA molecules connected together with copyspace] AnthiaCumming/E+ via Getty Images * Schrödinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) said that the U.S. FDA granted Fast Track status to its MALT1 inhibitor, SGR... Full story

Yahoo Finance • 8 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR).  Such investors are advised to contact Danielle Peyton at new... Full story

Yahoo Finance • 8 months ago

Schrödinger slides after early-stage trial data for cancer therapy

[Diffuse large B-cell lymphoma (DLBCL) - closeup view 3d illustration] Nemes Laszlo Shares of Schrödinger (NASDAQ:SDGR [https://seekingalpha.com/symbol/SDGR]) fell on Thursday after the AI-focused biotech posted initial data from a Phase... Full story

Yahoo Finance • 9 months ago

Stocks making the biggest moves midday: D-Wave Quantum, Moderna, Agilysys, Tesla and more

Check out the companies making headlines in midday trading. D-Wave Quantum — The quantum computing stock surged more than 26% after announcing its latest computing system called Advantage2. Agilysys — The enterprise software developer for... Full story

Yahoo Finance • 10 months ago

Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential

We recently published a list of Bill Gates’ 10 Stock Positions with Huge Upside Potential. In this article, we are going to take a look at where Schrödinger, Inc. (NASDAQ:SDGR) stands against other top stocks in Bill Gates’ portfolio with... Full story